Eighteen patients with severe Rh haemolytic disease, all of whom underwent fetal blood sampling and intrauterine transfusion, were studied. Twelve babies survived (67%) all of whom were delivered by lower segment caesarean section. There were three intrauterine deaths resulting in late abortion, one stillbirth with trisomy 21, and two neonatal deaths (both from severe prematurity). The traditional prognostic indicators were all inaccurate, and fetal blood sampling and measurement of the fetal packed cell volume were the most direct methods of assessing haemolysis. The progression of severe Rh disease is unpredictable, and we believe that all cases should be referred to specialist centres for advice or treatment.
Patients and methods Eighteen patients with fetuses severely affected by Rh haemolytic disease were treated from 1986 until the end of July 1988. They had a total of 50 previous pregnancies, five of which had ended before 28 weeks' gestation because of Rh disease; 45 were delivered after 28 weeks of which eight were stillbirths and one died in the neonatal period (20%).
Indications for treatment during their current pregnancies were: (i) an obstetric history of a previously affected baby with a cord haemoglobin concentration of less than 100 g/l, a baby requiring exchange or top up transfusions, a fetus requiring intrauterine transfusion, or a previous pregnancy resulting in a late abortion, stillbirth or neonatal death from Rh disease; (ii) a change in the optical density 450 of the amniotic fluid, indicating the need for intervention using 'Whitfield's action line'6; and (iii) ultrasonographic evidence of hydrops-for example, ascites, skin oedema, and pericardial or pleural effusions.
Fetal blood samples were all taken with a 20 gauge needle and a needle guide attached to a 5 mHz sector transducer (Diasonics, DRF 400). Samples were immediately checked to make sure that they were fetal in origin, and the packed cell volume was used to calculate the amount of donor blood required to raise the fetal packed cell volume to 0 40.7 Coombs's test, karyotype, blood grouping, infection screen, and biochemical analysis were also carried out on this first sample.
Patients were given oral lorazepam 4 mg and cephradine 500 mg two hours before the procedure, intramuscular papaveretum 10 mg and perphenazine 5 mg one hour before the procedure for pain relief, prophylaxis of infection, and to reduce fetal activity. Diuretics, inotropic or chronotropic drugs, and muscle relaxants were not used. No patient underwent plasmapheresis,8 and by the time of referral all had raised antibody concentrations (mean=40 IU/ml, range=11-256 IU/ml). The initial fetal blood samplings were carried out at a mean gestational age of 25 weeks (range= 18-31), the mean packed cell volume being 0-20 (range 0-08-0-32).
They underwent a total of 72 transfusions: intravascular alone (n= 39), intraperitoneal alone (n= 14), intravascular (n=8) with additional elective intraperitoneal transfusions (n= 8), which were counted as separate procedures. Three intracardiac transfusions were done because of technical problems with cordocentesis. The mean number of transfusions per patient was four (range 0-9). We failed to cannulate the cord 19 times, nine times because the fetus moved.
The data have been divided into groups based on the baby's condition at delivery in the last pregnancy, as this was thought to be the most important prognostic indicator: mild-Coombs's test positive, baby possibly needing phototherapy but no transfusion; moderate-exchange or top up transfusion needed after delivery, and severe-previous late abortion, stillbirths, or neonatal death, cord haemoglobin <100 g/l at delivery or previous intrauterine transfusion. Results The timing of the 'sensitising event', the Liley zone of the first sample of amniotic fluid taken, the change in antibody content, the ultrasound appearances at presentation, the packed cell volume at the time of first fetal blood sampling, and the mean gestational age at The mean antibody concentration in the blood at the time of booking varied with the severity of the past obstetric history, and patients in the severe group were more likely to have higher mean antibody concentrations in early pregnancy than those in the mild group. By the time of the first fetal blood sample, however, the difference between the mild and severe groups had disappeared. There was a noticeable difference between groups when the 'increase to maximum antibody concentration' was considered. There Direct measurement of the packed cell volume of the fetus gives precise information about the progress of the disease and permits accurate calculation of the volume of blood required for transfusion. Other 'causes' of fetal hydrops may also be excluded, and the fetal karyotype assessed.
The figure shows the changes in the fetal packed cell volume with repeated intrauterine transfusions in one patient, and shows the typical peaks after transfusion and troughs beforehand. As treatment proceeds, fetal red cells disappear as a result of destruction and marrow suppression. The packed cell volume stabilises, so that the interval between treatments may be lengthened; these may be further extended by combining intraperitoneal and intravenous transfusion.
SENSITISING EVENTS
A good case can be made for the introduction of routine antenatal prophylaxis with anti-D, which appears to reduce the incidence of 'silent' antenatal sensitisation; seven of the 17 patients in whom the method of sensitisation was known became sensitised in this way. Of concern is the large proportion of patients who never received any anti-D at the time of a sensitising event or at delivery.
CONCLUSION
Rh haemolytic disease is still a serious problem for those few affected pregnancies and it is unlikely to disappear. Although it is a rare condition it necessitates intensive management from both obstetric and paediatric units. All potentially affected cases, possibly with the exception of patients with only traces of antibodies, should be referred as early as possible to a regional unit for either advice or treatment. This need is emphasised by the rather unpredictable course that Rh disease now seems to follow.
